Technical Merit Is Not a Commercialization Strategy
Strong science can earn reviewer attention, but credible commercialization shows how an SBIR/STTR innovation moves from technical success to adoption.
Strong science can earn reviewer attention, but credible commercialization shows how an SBIR/STTR innovation moves from technical success to adoption.
HHS will limit SBIR/STTR applicants to nine proposals annually, forcing companies to rethink submission volume and funding strategy.
AI strengthens proposals only when ownership is clear. Reviewers focus on IP, data rights, and commercialization risk, not technical buzzwords.